Jäderling, Fredrik
Bergman, Martin
Engel, Jan Chandra
Mortezavi, Ashkan
Picker, Wolfgang
Haug, Erik Skaaheim
Eklund, Martin
Nordström, Tobias
Article History
Received: 15 January 2024
Accepted: 25 July 2024
First Online: 7 August 2024
Declarations
:
: The ethical review authority of Sweden and the regional ethics committee of Oslo approved the study (Swedish ethical review authority, Dnr. 2016/392–31 and Regional Comittees for Medical Research Ethics South East Norway, Dnr. 2016/684). Prior to inclusion, patients provided written informed consent to participate in the study.
: Not applicable.
: Martin Eklund report four pending prostate cancer diagnostic-related patents: method for indicating a presence or non-presence of aggressive prostate cancer (WO2013EP7425920131120); prognostic method for individuals with prostate cancer (WO2013EP7427020131120); method for indicating a presence of prostate cancer in individuals with particular characteristics (WO2018EP5247320180201); and method for indicating the presence or non-presence of prostate cancer (WO2013SE5055420130516). The Karolinska Institutet collaborates with A3P Biomedical in developing the technology for the Stockholm3 test. Martin Eklund and Tobias Nordström report owning shares in A3P Biomedical. All other authors declare no competing interests.All other authors declare no competing interests.